How much funding has Arkuda Therapeutics raised?

Arkuda Therapeutics has raised $108.0M in total funding, most recently a Series A round.

Who are Arkuda Therapeutics's investors?

Arkuda Therapeutics's investors include Atlas Venture, Pfizer Ventures, Tekla Capital Management, Cormorant Asset Management, Eli Lilly, Mission BioCapital.

When was Arkuda Therapeutics founded?

Arkuda Therapeutics was founded in 2018.

Where is Arkuda Therapeutics headquartered?

Arkuda Therapeutics is headquartered in Watertown, Massachusetts, United States.

What industry is Arkuda Therapeutics in?

Arkuda Therapeutics operates in Biotech, Healthcare.

How many employees does Arkuda Therapeutics have?

Arkuda Therapeutics has 11-50 employees.

Arkuda Therapeutics

Discovering therapies to change the trajectory of neurodegenerative disease

Watertown, United States · Founded 2018 · $108.0M raised

Biotech

Healthcare

Headquarters: Watertown, Massachusetts
Employees: 11–50
Founded: 2018
Business Model: B2B

Website: arkudatx.com
Total Funding: $108.0M
Last Round: $44.0M Series AFeb 2022
Rounds: 2

About

Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Founded in 2018 by Atlas Venture alongside scientists Gerhard Koenig and Duane Burnett, the company is based in Watertown, Massachusetts. Its lead program, ARKD-104, is a first-in-class oral development candidate targeting progranulin deficiency and lysosomal dysfunction in patients with GRN-related frontotemporal dementia and other neurodegenerative disorders. In 2024, Arkuda entered an option and asset purchase agreement with Johnson & Johnson Innovation, validating the company's scientific approach to precision neuroscience.

Summary

Arkuda Therapeutics is a Biotech company based in Watertown, United States, founded in 2018. It has raised $108.0M in total across 2 rounds, most recently a $44.0M Series A round in Feb 2022. Investors include Atlas Venture, Pfizer Ventures and Tekla Capital Management.